-DOCSTART- -X- O
Recently -X- _ O
identified -X- _ O
broadly -X- _ O
neutralizing -X- _ O
antibodies -X- _ O
( -X- _ O
bnAbs -X- _ O
) -X- _ O
show -X- _ O
great -X- _ O
potential -X- _ O
for -X- _ O
clinical -X- _ O
interventions -X- _ O
against -X- _ O
HIV-1 -X- _ B-Patient
infection. -X- _ I-Patient
However -X- _ O
, -X- _ O
resistant -X- _ O
strains -X- _ O
may -X- _ O
impose -X- _ O
substantial -X- _ O
challenges. -X- _ O
Here -X- _ O
, -X- _ O
we -X- _ O
report -X- _ O
on -X- _ O
the -X- _ O
identification -X- _ O
and -X- _ O
characterization -X- _ O
of -X- _ O
a -X- _ O
panel -X- _ O
of -X- _ O
HIV-1 -X- _ O
strains -X- _ O
with -X- _ O
broad -X- _ O
and -X- _ O
potent -X- _ O
resistance -X- _ B-Intervention
against -X- _ I-Intervention
a -X- _ I-Intervention
large -X- _ I-Intervention
number -X- _ I-Intervention
of -X- _ I-Intervention
bnAbs -X- _ I-Intervention
, -X- _ O
particularly -X- _ O
those -X- _ O
targeting -X- _ O
the -X- _ O
CD4-binding -X- _ O
site -X- _ O
( -X- _ O
CD4bs -X- _ O
) -X- _ O
. -X- _ O
Site-directed -X- _ O
mutagenesis -X- _ O
revealed -X- _ O
that -X- _ O
several -X- _ B-Outcome
key -X- _ I-Outcome
epitope -X- _ I-Outcome
mutations -X- _ I-Outcome
facilitate -X- _ I-Outcome
resistance -X- _ I-Outcome
and -X- _ I-Outcome
are -X- _ I-Outcome
located -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
inner -X- _ I-Outcome
domain -X- _ I-Outcome
, -X- _ I-Outcome
loop -X- _ I-Outcome
D -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
β23 -X- _ I-Outcome
/ -X- _ I-Outcome
loop -X- _ I-Outcome
V5 -X- _ I-Outcome
/ -X- _ I-Outcome
β24 -X- _ I-Outcome
of -X- _ I-Outcome
HIV-1 -X- _ I-Outcome
gp120. -X- _ I-Outcome
The -X- _ O
resistance -X- _ O
is -X- _ O
largely -X- _ O
correlated -X- _ O
with -X- _ O
binding -X- _ O
affinity -X- _ O
of -X- _ O
antibodies -X- _ O
to -X- _ O
the -X- _ O
envelope -X- _ O
trimers -X- _ O
expressed -X- _ O
on -X- _ O
the -X- _ O
cell -X- _ O
surface. -X- _ O
Our -X- _ O
results -X- _ O
therefore -X- _ O
demonstrate -X- _ O
the -X- _ O
existence -X- _ O
of -X- _ O
broadly -X- _ O
resistant -X- _ O
HIV-1 -X- _ O
strains -X- _ O
against -X- _ O
CD4bs -X- _ O
neutralizing -X- _ O
antibodies. -X- _ O
Treatment -X- _ O
strategies -X- _ O
based -X- _ O
on -X- _ O
the -X- _ O
CD4bs -X- _ O
bnAbs -X- _ O
must -X- _ O
overcome -X- _ O
such -X- _ O
resistance -X- _ O
to -X- _ O
achieve -X- _ O
optimal -X- _ O
clinical -X- _ O
outcomes -X- _ O
. -X- _ O

